医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Harbour BioMed Appoints Atul Deshpande, Ph.D. MBA, Chief Strategy Officer and Head of U.S. Operations

2019年01月04日 PM05:00
このエントリーをはてなブックマークに追加


 

SHANGHAI & CAMBRIDGE, Mass. & ROTTERDAM, Netherlands

Harbour BioMed announced the appointment of Atul Deshpande, Ph.D. MBA, as Chief Strategy Officer and Head of U.S. Operations. Dr. Deshpande joins Harbour BioMed from Sanofi, where he served as Global Operations Lead of Sanofi Genzyme’s Dupixent® (dupilumab) franchise.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190104005113/en/

Atul Deshpande, Chief Strategy Officer and Head of U.S. Operations, Harbour BioMed. (Photo: Business ...

Atul Deshpande, Chief Strategy Officer and Head of U.S. Operations, Harbour BioMed. (Photo: Business Wire)

“Atul brings a wealth of industry experience in immunology and other therapeutic areas and across the pharmaceutical value chain, including both strategy and execution,” said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. “Harbour BioMed has rapidly expanded its drug discovery platforms and built an initial R&D portfolio since it was founded two years ago. Atul will be integral to developing and driving corporate strategy for the next stage of our growth. He will also oversee our U.S. business operations.”

During his tenure at Sanofi Genzyme, Dr. Deshpande delivered on roles with increasing responsibility from strategy to implementation. He was instrumental in establishing and executing global Dupixent launches in Atopic Dermatitis and Asthma, a blockbuster brand in the making. He also brings significant international experience, having developed the R&D strategy for the company’s Asia Pacific businesses, including Japan and China. Prior to Sanofi Genzyme, Dr. Deshpande served at several life science strategic consulting firms.

Dr. Deshpande holds a Ph.D. in Neurobiology and Behavior from University of California, Irvine and an MBA from Cranfield University in the UK.

Company Also Names Chief Development, Chief Business Officers

Harbour BioMed also announced the promotions of Dr. Xiaoxiang Chen, MD to Chief Development Officer, and Dr. Mai-Jing Liao, Ph.D., MBA to Chief Business Officer, effective immediately.

About Harbour BioMed

Harbour BioMed is a global biopharmaceutical company discovering and developing innovative therapeutics for oncology and immunological diseases. The company’s discovery and development programs are built around its two patented transgenic mouse platforms for therapeutic antibody discovery. The company is building a proprietary pipeline through its innovative internal discovery programs, and through in-licensing clinical stage assets that strategically fit its internal portfolio. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary. For more information, visit www.harbourbiomed.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190104005113/en/

CONTACT

Timothy Miller, Harbour Antibodies US, Boston
+1-857-214-0976
timothy.miller@harbourbiomed.com

Yue Wang, Harbour BioMed, Shanghai
+86-138-1854-2349
yue.wang@harbourbiomed.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • SpinalCyte在China Focus @ Europe Vienna上进行呈报
  • デンタル・モニタリングがビトルビアンと提携して革新的AIソリューションの世界的普及を促進
  • InterSystems IRIS for Health Empowers MediWay Technology to Accelerate the Digital Transformation of Healthcare in China
  • SpeeDx经销网络扩展至中东
  • SpeeDxの販売ネットワークが中東に拡大